Allegro Ophthalmics

Executive Summary

Allegro Ophthalmics is a private clinical-stage biopharmaceutical company developing novel integrin-regulating therapies for ocular diseases with high unmet need. Its lead candidate, risuteganib (Luminate®), is a first-in-class mitochondrial stabilizer that restores retinal homeostasis by targeting multiple oxidative stress pathways. The company is advancing risuteganib in Phase 3 trials for intermediate dry age-related macular degeneration (AMD) and dry eye disease. Despite a lengthy development timeline since its founding in 2007, Allegro has generated promising early data and continues to progress toward pivotal readouts. With a focused pipeline and a differentiated mechanism of action, Allegro represents a potential near-term value inflection in the ophthalmic space, assuming successful trial outcomes. The company remains private, so financing and partnership catalysts are also key.

Upcoming Catalysts (preview)

• H2 2026Phase 3 dry AMD top-line data readout55% success
• H1 2027Phase 3 dry eye disease trial results50% success
• 2026Strategic partnership or licensing deal for risuteganib40% success